Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Reports First Half 2019 Financial Results and Provides Corporate Update
October 03, 2019 12:00 ET | Quantum Genomics
Arterial hypertension: preparing for the pivotal Phase III study of firibastat in patients with resistant arterial hypertension           Heart failure: the first patients were enrolled in June in...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Launches Study of Firibastat in Patients with Renal Failure
September 11, 2019 13:34 ET | Quantum Genomics
PARIS and NEW YORK, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that a...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Announces Positive FDA Feedback on Phase III Program Design of Firibastat in Resistant Arterial Hypertension
September 02, 2019 12:00 ET | Quantum Genomics
PARIS and NEW YORK, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Selected to Enter the European Rising Tech Label
July 03, 2019 12:00 ET | Quantum Genomics
PARIS and NEW YORK, July 03, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC),  a biopharmaceutical company specializing in the development of a new drug class that...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Announces Result of Annual General Meeting
June 27, 2019 12:00 ET | Quantum Genomics
PARIS and NEW YORK, June 27, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical...
Logo_Quantum_Genomics-iloveimg-resized.png
A key milestone reached by Quantum Genomics in the development of firibastat
June 12, 2019 12:00 ET | Quantum Genomics
A novel 500 mg controlled-release tablet of firibastat offering an optimal pharmacokinetic profile for once-a-day dosing has been identified PARIS and NEW YORK, June 12, 2019 (GLOBE NEWSWIRE) --...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat in Heart Failure Patients
June 06, 2019 12:00 ET | Quantum Genomics
PARIS and NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Announces the Publication of a New Scientific Article in the Journal Hypertension
May 10, 2019 09:47 ET | Quantum Genomics
PARIS and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Announces the Publication of its Phase IIb NEW-HOPE Study Results of Firibastat in Arterial Hypertension in the Journal Circulation
April 26, 2019 08:00 ET | Quantum Genomics
PARIS and NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Receives First Regulatory and Ethics Approvals to Initiate Phase IIb QUORUM Study of Firibastat in Heart Failure
April 17, 2019 12:00 ET | Quantum Genomics
PARIS and NEW YORK, April 17, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth: ALQGC, OTCQX: QNNTF), a biopharmaceutical company specializing in the development of a new drug class that...